and/or as mammalian conjugates produced by a combination of Omethylation, glucuronidation and/or sulfation post-absorption (Baba et al., 2001a; Baba et al., 2002; Gonthier et al., 2003b) . It has been demonstrated that some flavan-3-ol conjugates (e.g. the 5-β-D-glucuronides) but not all (e.g. 3`-O-methyl) retain their in vitro antioxidant activity (Harada et al., 1999) . However, it has been suggested that their transient occurrence and low concentrations in plasma, and relatively high redox potential compared with tocopherols and ascorbate, make it unlikely that their antioxidant properties explain any possible benefit to health and that alternative mechanisms should be sought and evaluated (Clifford, 2004) .
The objective of the current study was to investigate in vivo in male rats the DMD 30304 Animals. Wistar albino rats (WA), specific pathogen free (SPF), 200-250 g were purchased from B&K Universal Ltd (Hull, UK). The animals were kept in controlled conditions within the provisions of Home Office license, UK, and were adapted for one week (12 h dark-light cycle), constant temperature 22 ± 1 o C, and 50 % humidity and with free access to a standard rodent diet (B&K Universal) and water. The animals were weighed and were divided randomly into three groups (I-III). For the intravenous administration (I), NaCl was added to [
14 C] procyanidin B2, to make a solution of 0.9 % saline and a single dose was applied via the caudal vein (~150 µL/animal) adjusted to provide a dose of 21 mg Kg -1 body weight for each animal. For the oral administration, a single dose was applied, approximately 500 µL/animal, adjusted to provide a dose of 21 mg Kg -1 (II) and 10.5 mg Kg -1 (III) of body weight for each rat. The weight of the gavage syringe used to deliver the dose was recorded before and after dosing and the exact amount administered to each rat was calculated by mass difference.
Mass balance and blood pharmacokinetics. After dosing rats were housed individually in metabolic cages (Arrowmight Biosciences, Hereford, UK) and urine and feces were collected daily for four days at time points of 0, 24, 48, 72 and 96 h after dosing. For the blood pharmacokinetics, approximately 2 mm was removed from the end of the tail with a scalpel blade and blood samples (0.1 mL) were collected at regular intervals covering a time scale between 0.5 and 24 h (sampling: 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 15, 18, 20, 22 and 24 h) into lithium-heparinized centrifuge microtubes. and fitted to a non-compartmental model. Animal data were analyzed individually and are presented as mean ± SD for nine animals.
Mass balance analysis.

Results
Mass balance. Excretion of radioactivity from 0 to 96 h was higher in urine than in feces (table 1) . During the first 24 h post-administration, ~69 % of the dose was excreted in urine for the intravenous group (I) while ~58 % was recovered for both oral groups (II and III). Total urinary excretion at the end of the collection period was calculated as ~76 % after intravenous dosing (group I) and 62-63 % after oral dosing (groups II and III) This article has not been copyedited and formatted. The final version may differ from this version. and ~99 % respectively (≤ 24 h post-administration). Low levels of total radioactivity were excreted even 96 h after administration for all three groups of animals (I, II and III).
The sum of total radioactivity collected from urine and feces in all three groups of animals suggests full recovery (103.2 ± 7.2%) within experimental error. Results are the mean ± SD for five animals.
Bioavailability ( This article has not been copyedited and formatted. The final version may differ from this version. (table 2) reflecting the difference in the compounds being monitored. In the present study, a significant level of radioactivity was detected in blood even at 0.5 h after oral administration suggesting that some of the [ 14 C] procyanidin B2 was absorbed in the stomach or upper GI tract, probably in the intact form (figure 5). However, the maximal concentrations (C max ) for total [ 14 C] in blood were not attained until 5 to 6 h after oral administration suggesting that much of the radioactivity was absorbed from the distal part of the small intestine and/or the colon. Taken collectively, these data strongly suggest that much of the radioactivity detected in the blood after oral administration is derived from low-molecular weight phenolic acids and other compounds produced from procyanidin B2 by microorganisms in the gut prior to absorption as has been previously demonstrated for procyanidin B3 by rat cecal microflora (Gonthier et al., 2003b) , crude proanthocyanidins by human colonic microflora (Deprez et al., 2000) and procyanidin B2
by human colonic microflora (Stoupi et al., 2009) 
in vitro.
Similar observations have been made previously, but have been explained by suggesting that the major bioavailable form of procyanidin dimers (B2 and B5) was (−)-epicatechin formed by depolymerization based on studies using an in vitro small intestinal model (Spencer et al., 2001) . Subsequent studies in humans demonstrated that this values, and most of the radioactivity is absorbed from the distal part of the small intestine and/or the colon (T max ≈ 6 h). These data suggest that a greater fraction of the parent compound is transformed by the gut microflora and that it may be these metabolites that are responsible for any biological activities or health benefits that might be associated with proanthocyanidin consumption.
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